Screen Older Heart Failure Patients for Transthyretin Cardiac Amyloidosis

Name: Relias Media
Price range: $

October 1, 2021

A screening study of heart failure patients ≥ age 60 years, left ventricular ejection fraction ≥ 40%, and left ventricle wall thickness ≥ 12 mm revealed 6.3% prevalence of transthyretin cardiac amyloidosis, a highly treatable disease.

Issue Date: October 1, 2021

Table of Contents

Screen Older Heart Failure Patients for Transthyretin Cardiac Amyloidosis
Slow, Steady, and Synchronized Wins the Race
Early Coronary Angiography in Out-of-Hospital Cardiac Arrest
First-Line Therapy for Hypertension
Progression of Coronary Calcium on Statin Treatment

Financial Disclosure: Dr. Joshua Moss, author, reports he is a consultant for Abbott and Biosense Webster. The relevant financial relationships listed have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements